cme-20201110false000115637500011563752020-11-102020-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________
FORM 8-K
_________________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) November 10, 2020
_________________________________________________________
CME GROUP INC.
(Exact Name of Registrant as Specified in Charter)
_________________________________________________________
| | | | | | | | | | | | | | |
Delaware | | 001-31553 | | 36-4459170 |
(State or Other Jurisdiction of Incorporation) | | (Commission File No.) | | (IRS Employer Identification No.) |
| | | | | | | | | | | | | | |
| | | | |
20 South Wacker Drive | Chicago | Illinois | | 60606 |
(Address of Principal Executive Offices) | | | | (Zip Code) |
Registrant’s telephone number, including area code: (312) 930-1000
N/A
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading symbol | Name of each exchange on which registered |
Class A Common Stock | CME | Nasdaq |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | | | | |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | | | | |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| | | | | |
Item 7.01 | Regulation FD Disclosure. |
To allow additional time for client readiness in the current environment, CME Group is moving the migration date of BrokerTec to Globex. BrokerTec Europe will migrate on January 18 and BrokerTec U.S. will follow on February 1. CME Group also announced that 2020 synergy estimates will not be impacted as a result of the change in dates.
The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.
| | | | | |
Item 9.01 | Financial Statements and Exhibits. |
| | | | | | | | |
| | |
Exhibit Number | | Description |
| |
| | |
104 | | | The cover page from CME Group Inc.'s Current Report on Form 8-K, formatted in Inline XBRL. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | | | | |
| | | | |
| | CME Group Inc. |
| | Registrant |
| | |
Date: November 10, 2020 | | By: | | /s/ Kathleen M. Cronin |
| | Name: | | Kathleen M. Cronin |
| | Title: | | Senior Managing Director, General Counsel and Corporate Secretary |